The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial.

scientific article published on 4 December 2013

The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.AHJ.2013.11.010
P698PubMed publication ID24576513

P50authorG. Ardine de WitQ60669638
P2093author name stringKit C B Roes
Michiel L Bots
Wilko Spiering
Peter J Blankestijn
Michiel Voskuil
Esther de Beus
Eva E Vink
Evert-Jan Vonken
Rosa L de Jager
P2860cites workPredictive validity of a medication adherence measure in an outpatient settingQ36925564
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectpharmacologyQ128406
P304page(s)308-314.e3
P577publication date2013-12-04
P1433published inAmerican Heart JournalQ2227156
P1476titleThe effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial
P478volume167

Reverse relations

cites work (P2860)
Q36219271Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension
Q48226482Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial.
Q38755127Renal denervation for resistant hypertension.
Q50000414Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension.

Search more.